17 results on '"Zielinski C"'
Search Results
2. ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care—a tale stretching over 8 years
- Author
-
Zielinski, C., primary, Preusser, M., additional, and Berghoff, A., additional
- Published
- 2023
- Full Text
- View/download PDF
3. ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
- Author
-
Cherny, N.I., Sullivan, R., Dafni, U., Kerst, J.M., Sobrero, A., Zielinski, C., Piccart, M.J., Bogaerts, J., Tabernero, J., Latino, N.J., and de Vries, Ege
- Published
- 2016
- Full Text
- View/download PDF
4. Introducing pro and con discussions in ESMO Open—Cancer Horizons
- Author
-
Zielinski, C., primary, Preusser, M., additional, and Berghoff, A., additional
- Published
- 2022
- Full Text
- View/download PDF
5. ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
- Author
-
Pentheroudakis, G., primary, Curigliano, G., additional, and Zielinski, C., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Professor Gouri Shankar Bhattacharyya
- Author
-
Zielinski, C., primary
- Published
- 2021
- Full Text
- View/download PDF
7. Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment.
- Author
-
Morgan G, Preusser M, and Zielinski C
- Subjects
- Humans, Periodicals as Topic, Societies, Medical, Neoplasms, Precision Medicine
- Published
- 2020
- Full Text
- View/download PDF
8. Awareness of predatory journals and open access among medical oncologists: results of an online survey.
- Author
-
Richtig G, Richtig E, Böhm A, Oing C, Bozorgmehr F, Kruger S, Kiesewetter B, Zielinski C, and Berghoff AS
- Subjects
- Adult, Aged, Austria, Female, Germany, Humans, Male, Middle Aged, Oncologists psychology, Open Access Publishing standards, Periodicals as Topic ethics, Prospective Studies, Surveys and Questionnaires statistics & numerical data, Awareness, Oncologists statistics & numerical data, Open Access Publishing ethics, Peer Review standards
- Abstract
Introduction: Predatory journals harm the integrity of science as principles of 'good scientific practice' are bypassed by omitting a proper peer-review process. Therefore, we aimed to explore the awareness of predatory journals among oncologists., Methods: An online survey among oncologists working in Germany or Austria of various professional surroundings was conducted between October 2018 and April 2019., Results: One hundred and eighty-eight participants (55 women (29.2%), 128 men (68.1%)) completed the questionnaire. 41 (21.8%) participants indicated to work in a hospital, 24 (12.8%) in private practice and 112 (59.6%) in a university hospital. 98.9% of participants indicated to actively read scientific articles and consider them in clinical decision-making (96.3%). 90.4% of participants indicated to have scientific experience by publishing papers in journals with peer-review system. The open-access system was known by 170 (90.4%), predatory journals by 131 (69.7%) and Beall's list by 52 participants (27.7%). Predatory journals were more likely to be known by participants with a higher number of publications (p<0.001), with more high-impact publications (p=0.005) and with recent publications (p<0.001). Awareness of predatory journals did not correlate with gender (p=0.515) or translation of scientific literature into clinical practice (p=0.543)., Conclusions: The problematic topic of 'predatory journals' is still unknown by a considerable amount of oncologist, although the survey was taken in a cohort of oncologists with scientific experience. Dedicated educational initiatives are needed to raise awareness of this problem and to aid in the identification of predatory journals for the scientific oncology community., Competing Interests: Competing interests: ASB has research support from Daiichi Sankyo (≤ €10 000), Roche (> €10 000) and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo (all < €5000) as well as travel support from Roche, Amgen and AbbVie., (© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.)
- Published
- 2019
- Full Text
- View/download PDF
9. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
- Author
-
Wilking N, Bucsics A, Kandolf Sekulovic L, Kobelt G, Laslop A, Makaroff L, Roediger A, and Zielinski C
- Subjects
- Antineoplastic Agents economics, Clinical Trials as Topic, Cost-Benefit Analysis, Drug Approval economics, Drug Industry economics, Drug Industry organization & administration, Drugs, Investigational economics, European Union, Humans, Interdisciplinary Communication, Medical Oncology economics, Neoplasms economics, Reimbursement Mechanisms economics, Reimbursement Mechanisms organization & administration, Time Factors, Antineoplastic Agents therapeutic use, Drug Approval organization & administration, Drugs, Investigational therapeutic use, International Cooperation, Medical Oncology organization & administration, Neoplasms drug therapy
- Abstract
The Central European Cooperative Oncology Group (CECOG) and 'ESMO Open-Cancer Horizons' roundtable discussion brought together stakeholders from several European Union (EU) countries involved in drug development, drug authorisation and reimbursement or otherwise affected by delayed and unequal access to innovative anticancer drugs. The approval process of drugs is well established and access delays can be caused directly or indirectly by national or regional decision-making processes on reimbursement. The two key aspects for those involved in reimbursement decisions are first the level of evidence required to decide and second pricing, which can be challenging for some innovative oncology compounds, especially in Eastern and South-Eastern European countries. Other important factors include: available healthcare budget; the structure and sophistication of healthcare authorities and health technology assessment processes; societal context and political will. From the point of view of the pharmaceutical industry, better alignment between stakeholders in the process and adaptive pathway initiatives is desirable. Key aspects for patients are improved access to clinical trials, preapproval availability and reports on real-world evidence. Restricted access limits oncologists' daily work in Eastern and South-Eastern EU countries. The roundtable discussion suggested considering the sequencing of regulatory approval and reimbursement decisions together with more flexible contracting as a possible way forward. The panel concluded that early and regular dialogue between all stakeholders including regulators, payers, patient stakeholders and industry is required to improve the situation., Competing Interests: Competing interests: The current work of AB (for MoCA and as unpaid expert for the Austrian Federal Administrative Court) informs about payers’ attitudes/concerns regarding the reimbursement of expensive medicines. However, the opinions expressed here cannot be construed as an official position of any payer organisation. LKS received relevant financial funding for activities outside the submitted work, which are speaker’s fees from Roche, Novartis, BMS and MSD. GK received relevant financial funding outside the submitted work from MSD. AL: the views expressed in this article are the personal views of the the co-author and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties. LM is a paid employee of Fight Bladder Cancer UK, and a volunteer board member of the World Bladder Cancer Patient Coalition. Fight Bladder Cancer UK has received financial support from BMS, Janssen, MSD and F. Hoffman-La Roche AG. The World Bladder Cancer Patient Coalition has received financial support from AstraZeneca, Bayer, F. Hoffman-La Roche AG, Janssen, Ipsen, MSD and Photocure. AR is an employee of MSD International and owns shares of MSD. MSD has supported this meeting together with Boehringer Ingelheim. NW received project grants and consulting and speaking fees from a large number of pharmaceutical companies, including MSD. CZ received honoraria from Roche, Novartis, BMS, MSD, Imugene, Ariad, Pfizer, Merrimack/Shire, Merck KGaA, Fibrogen, AstraZeneca, Tesaro, Gilead, Servier, Eli Lilly and Amgen., (© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.)
- Published
- 2019
- Full Text
- View/download PDF
10. CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion.
- Author
-
Awada A, Gligorov J, Jerusalem G, Preusser M, Singer C, and Zielinski C
- Subjects
- Antineoplastic Agents, Hormonal economics, Antineoplastic Agents, Hormonal pharmacology, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols economics, Antineoplastic Combined Chemotherapy Protocols standards, Aromatase Inhibitors economics, Aromatase Inhibitors pharmacology, Aromatase Inhibitors therapeutic use, Breast drug effects, Breast pathology, Breast surgery, Breast Neoplasms economics, Breast Neoplasms mortality, Breast Neoplasms pathology, Chemotherapy, Adjuvant economics, Chemotherapy, Adjuvant methods, Chemotherapy, Adjuvant standards, Clinical Protocols standards, Clinical Trials as Topic, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Female, Humans, Mastectomy, Progression-Free Survival, Protein Kinase Inhibitors economics, Protein Kinase Inhibitors pharmacology, Tumor Burden drug effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms therapy, Practice Guidelines as Topic, Protein Kinase Inhibitors therapeutic use
- Abstract
In December 2017, ESMO Open-Cancer Horizons convened a round-table discussion on the background and latest data regarding cyclin-dependent kinase (CDK)4/6 inhibitors with endocrine therapy (ET) in the treatment of endocrine-sensitive breast cancer (BC). A review on this discussion was published in summer 2018 (https://esmoopen.bmj.com/content/3/5/e000368).Endocrine-sensitive BC with non-visceral disease and limited spread of the metastases.Endocrine-sensitive BC with non-life-threatening visceral involvement. Several open questions were identified, which led to a second ESMO Open discussion on CDK4/6 inhibitors, taking place in December 2018 and covered in this article. The panel discussed two important clinical scenarios and the pro and cons of a treatment approach with CDK4/6 inhibitors for each scenario:Endocrine-sensitive BC with non-visceral disease and limited spread of the metastases.Endocrine-sensitive BC with non-life-threatening visceral involvement. Regarding scenario 1, the panel agreed that CDK4/6 inhibitors should be recommended in first-line therapy for most patients if cost and practicality allow. However, the use of single-agent ET with an aromatase inhibitor in the first-line treatment of these patients is still a possibility for a small group of patients with very limited disease, such as one or two bone lesions or limited lymph node involvement. Regarding scenario 2, chemotherapy is the first approach for patients with endocrine-sensitive metastatic BC with life-threatening visceral involvement because of the need for a faster response. The therapeutic approaches for patients with non-life-threatening visceral involvement are still under debate. Nevertheless, CDK4/6 inhibitors are currently the treatment of choice for most patients with a close follow-up of tumour response. A treatment algorithm has been suggested at the round table., Competing Interests: Competing interests: MP: honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo and Merck Sharp & Dome. JG: research support from Eisai, Genomic Health, Novartis, Pfizer and Roche; travel grants from Eisai, Genomic Health, Novartis, Pfizer and Roche; honoraria for advisory boards and speaker fees from Daiichi, Eisai, Genomic Health, Ipsen, Macrogenics, MSD, Novartis, Onxeo, Pfizer and Roche. GJ: grants, personal fees and non-financial support from Novartis and Roche; personal fees and non-financial support from Pfizer, Lilly, Amgen, BMS, Astra-Zeneca; personal fees from Celgene, Puma Technology, Daiichi Sankyo and Abbvie. AA: advisory boards, travel grants, speaker fees: Novartis, Roche, Lilly, Amgen, Eisai, BMS, MSD, LeoPharma, Genomic Health and Ipsen. CS: honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Novartis, Gerson Lehrman Group, Astra-Zeneca, Lilly, Roche, Amgen, Pfitzer, Merck KGaA, and Tesaro. CCZ: honoraria from Roche, Novartis, BMS, MSD, Imugene, Ariad, Pfizer, Merrimack, Merck KGaA, Fibrogen, AstraZeneca, Tesaro, Gilead, Servier and Shire., (© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.)
- Published
- 2019
- Full Text
- View/download PDF
11. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.
- Author
-
Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, Tonn JC, and Zielinski C
- Abstract
This article is the result of a round table discussion held at the European Lung Cancer Conference (ELCC) in Geneva in May 2017. Its purpose is to explore and discuss the advances in the knowledge about the biology and treatment of brain metastases originating from non -small cell lung cancer. The authors propose a series of recommendations for research and treatment within the discussed context., Competing Interests: Competing interests: MP: Research support from Boehringer-Ingelheim, GlaxoSmithKline, Merck Sharp and Dohme and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca and AbbVie. FW: Research support from Boehringer Ingelheim, Genentech and Roche. Honoraria for lectures, consultation and advisory board participation from UCB, Roche and Boehringer Ingelheim. CM: Honoraria from Lilly and Boehringer Ingelheim. EM: Research support from AstraZeneca, Merck KGaA, advisory board participation from Merck KGaA. CZ: Honoraria from Ariad, Novartis, Boehringer Ingelheim, Roche and AstraZeneca.
- Published
- 2018
- Full Text
- View/download PDF
12. ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO).
- Author
-
Ohe Y and Zielinski C
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2017
- Full Text
- View/download PDF
13. CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology.
- Author
-
Preusser M, Berghoff AS, Thallinger C, and Zielinski C
- Abstract
The blood-brain barrier (BBB) protects the central nervous system (CNS) from potentially harmful substances and molecules by limiting their influx from the blood stream into the brain parenchyma. Understanding the structure and functioning of the BBB is of major importance for the development of effective medical treatments for primary and secondary brain tumours. Therefore, we provide here a concise and illustrated educational description of the anatomy and physiology of the BBB and current concepts on its role for targeted cancer therapies and immuno-oncology., Competing Interests: Competing interests: None declared.
- Published
- 2017
- Full Text
- View/download PDF
14. One year of ESMO Open : Cancer Horizons -where are we going from here?
- Author
-
Zielinski C
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2017
- Full Text
- View/download PDF
15. The European Cancer Patient's Bill of Rights, update and implementation 2016.
- Author
-
Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Højgaard L, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Löwenberg B, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P, and Selby P
- Abstract
In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative:The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care.The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, underpinned by research and innovation.The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care. The key aspects of working towards implementing the BoR are:Agree our high-level goal. The vision of 70% long-term survival for patients with cancer in 2035, promoting cancer prevention and cancer control and the associated progress in ensuring good patient experience and quality of life.Establish the major mechanisms to underpin its delivery. (1) The systematic and rigorous sharing of best practice between and across European cancer healthcare systems and (2) the active promotion of Research and Innovation focused on improving outcomes; (3) Improving access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer diagnostic tests and treatments.Work with other organisations to bring into being a Europe based centre that will (1) systematically identify, evaluate and validate and disseminate best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise its impact to improve outcomes., Competing Interests: Competing interests: None declared.
- Published
- 2017
- Full Text
- View/download PDF
16. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015.
- Author
-
Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, Oton AB, Gomez H, Dafni U, Vallejos C, and Zielinski C
- Abstract
Latin America and the Caribbean have not yet developed strong clinical cancer research programmes. In order to improve this situation two international cancer organisations, the Latin American Society of Clinical Oncology (SLACOM) and the European Society of Medical Oncology (ESMO) worked closely with the Peruvian Cooperative Oncology Group (GECOPERU) and organised a clinical cancer research workshop held in Lima, Peru, in October 2015. Many oncologists from different Latin American countries participated in this gathering. The opportunities for and strengths of clinical oncology research in Latin American and Caribbean countries were identified as the widespread use of the Spanish language, the high cancer burden, growing access to information, improving patient education, access to new drugs for research centres, regional networks and human resources. However, there are still many weaknesses and problems including the long timeline for regulatory approval, lack of economic investment, lack of training and lack of personnel participating in clinical research, lack of cancer registries, insufficient technology and insufficient supplies for the diagnosis and treatment of cancer, few cancer specialists, low general levels of education and the negative attitude of government authorities towards clinical research., Competing Interests: Conflicts of Interest: None declared.
- Published
- 2016
- Full Text
- View/download PDF
17. Recent developments and translational aspects in targeted therapy for metastatic breast cancer.
- Author
-
Marhold M, Bartsch R, and Zielinski C
- Abstract
Biologically distinct subtypes of metastatic breast cancer (MBC) have been defined by multiple efforts in recent years, showing broad heterogeneity at the molecular level of disease. Throughout this endeavour, oncogenic drivers within MBC were identified as potential therapeutic targets. With recent results from clinical trials targeting these well-known cancer-promoting pathways, this review is trying to elucidate as well as summarise current new therapeutic aspects in MBC and shed light on translational aspects within this entity., Competing Interests: Conflicts of Interest: None declared.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.